Characteristics and Risk Factors of Oxaliplatin-related Hypersensitivity Reactions

被引:46
作者
Shao, Yu-Yun [1 ,5 ]
Hu, Fu-Chang [2 ]
Liang, Lin-Tung [3 ]
Chiu, Wen-Tzu [1 ]
Cheng, Ann-Lii [1 ,4 ]
Yang, Chih-Hsin [1 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10002, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 10002, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Surg, Taipei 10002, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10002, Taiwan
[5] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Oncol, Yunlin, Taiwan
关键词
chemotherapy; drug hypersensitivity; oxaliplatin; DESENSITIZATION SCHEDULE; CARBOPLATIN; LEUCOVORIN; EXPERIENCE; MANAGEMENT; CANCER;
D O I
10.1016/S0929-6646(10)60064-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: Hypersensitivity reactions during oxaliplatin infusion are a major problem associated with its use. In this study, we investigated the characteristics and risk factors of these events. Methods: All patients who had received oxaliplatin in outpatient settings from January 2006 to March 2007 in a medical center were enrolled in this retrospective study. All the oxaliplatin infusions were reviewed. Manifestations of hypersensitivity reactions and clinicopathological variables were collected from medical records. Results: Three hundred and eighty-three patients with 3648 oxaliplatin infusions were reviewed. Forty-seven patients (12.7%) developed hypersensitivity reactions, which occurred after a median of 10 infusions. The median time of onset from start of infusion was 40 minutes. most presentations (90.7%) were mild to moderate, but rechallenge with oxaliplatin led to a high chance of further reactions (71.4%). Cutaneous symptoms were the most prevalent manifestation, followed by respiratory symptoms. With each repeated infusion, the incidence of hypersensitivity reactions increased. Higher oxaliplatin dose per infusion was an independent risk factor for such reactions. Conclusion: Patients treated with oxaliplatin for an extended period have a greater risk of oxaliplatin-related hypersensitivity reactions.
引用
收藏
页码:362 / 368
页数:7
相关论文
共 23 条
  • [1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [2] [Anonymous], 2006, Common Terminology Criteria for Adverse Events Internet
  • [3] Hypersensitivity reactions related to oxaliplatin (OHP)
    Brandi, G
    Pantaleo, MA
    Galli, C
    Falcone, A
    Antonuzzo, A
    Mordenti, P
    Di Marco, MC
    Biasco, G
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 477 - 481
  • [4] de Vries HJC, 2006, INT J STD AIDS, V17, P4
  • [5] Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer
    deGramont, A
    Vignoud, J
    Tournigand, C
    Louvet, C
    Andre, T
    Varette, C
    Raymond, E
    Moreau, S
    LeBail, N
    Krulik, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (02) : 214 - 219
  • [6] Edmondson David A, 2007, Am J Ther, V14, P116, DOI 10.1097/01.pap.0000249924.90645.5b
  • [7] Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol
    Gammon, D
    Bhargava, P
    McCormick, MJ
    [J]. ONCOLOGIST, 2004, 9 (05) : 546 - 549
  • [8] Gowda A, 2004, ONCOLOGY-NY, V18, P1671
  • [9] KHAN A, 1975, CANCER RES, V35, P2766
  • [10] Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review
    Kim, Brian H.
    Bradley, Thomas
    Tai, Julia
    Budman, Daniel R.
    [J]. ONCOLOGY, 2009, 76 (04) : 231 - 238